title: Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
abstract: OBJECTIVE
  To assess the efficacy and the tolerability of flutamide as adjuvant treatment after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
  
  
  METHODS
  Men with locally advanced, lymph node-negative prostate cancer were randomized after radical prostatectomy to receive either flutamide 750mg daily or no adjuvant treatment. Recurrence-free and overall survival were the study end points. Recurrence was defined as a PSA value greater than 5ng/ml or two values greater than 2ng/ml more than three months apart with increasing tendency or three values greater than 1ng/ml more than three months apart with increasing tendency or any clinical recurrence.
  
  
  RESULTS
  309 patients (157 in the control arm and 152 in the flutamide arm) were eligible for efficacy analysis. The median follow-up was 6.1 years. Recurrence-free survival was better in the flutamide group ( P=0.0041), there was, however, no detectable difference in overall survival ( p=0.92 ). Moreover, there was a considerable toxicity reported in the flutamide group.
  
  
  CONCLUSIONS
  Although having some effect on disease recurrence, adjuvant flutamide treatment does not improve median-term overall survival after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
authors.affiliation: Department of Urology, University Hospital "Carl Gustav Carus", Technical University of Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany. manfred.wirth@mailbox.tu-dresden.de
authors.forename: Manfred P
authors.initials: MP
authors.lastname: Wirth
authors.forename: Lothar
authors.initials: L
authors.lastname: Weissbach
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Marx
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Heckl
authors.forename: Wilfried
authors.initials: W
authors.lastname: Jellinghaus
authors.forename: Hubertus
authors.initials: H
authors.lastname: Riedmiller
authors.forename: Birgit
authors.initials: B
authors.lastname: Noack
authors.forename: Axel
authors.initials: A
authors.lastname: Hinke
authors.forename: Michael
authors.initials: M
authors.lastname: Froehner
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide; D017430:Prostate-Specific Antigen